Future therapeutic approaches to Alzheimer's disease

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 11, 1998, Pages 14-16

  Davis, Kenneth L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; ESTROGENS; FORECASTING; FREE RADICAL SCAVENGERS; HUMANS; PALLIATIVE CARE;

EID: 0031715862     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Farlow M, Gracon SL, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529
2. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47:166-177
3. Davis KL, Thal LJ, Gamzu ER, et al. A double blind, placebo controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259
4. Altsteil L. Cholinomimetic therapy in AD: experience with the muscarinic agonist xanomeline. Presented at the 2nd annual conference in the Therapeutics of Alzheimer's Disease; June 1996; Garden City, NY
5. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer's b/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 1992;89: 10,075-10,078
6. Nitsch RM, Slack BE, Wurtman RJ, et al. Release of Alzheimer's amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-307
7. Lahiri D. Reversibility of the effect of tacrine on the secretion of the β-amyloid precursor protein in cultured cells. Neurosci Lett 1994;181: 142-149
8. Lahiri D, Lewis S, Farlow M. Tacrine alters secretion of the β-amyloid precursor protein in cell lines. J Neurosci Res 1994;37:777-787
9. Lahiri DK, Nail C, Farlow M. The cholinergic agonist carbachol reduces intracellular beta-amyloid protein in PC12 and C6 cells. Biochem Int 1992; 28:853-860
10. Wallace W, Liederberg I, Schink D, et al. Chronic evaluation of soluble amyloid precursor protein and amyloid beta peptide secretion in subcortically lesioned rats. J Neurosci 1995;15:4896-4905
11. Haroutunian V, Greig N, Pei X-F, et al. Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Mol Brain Res 1997;46(1,2):161-168
12. Haroutunian V, Greig N, Gluck R, et al. Selective attenuation of lesion-induced increases in secreted β-APP by acetylcholinesterase inhibitors. Soc Neurosci 1995;208:1
13. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994;151:1105-1113
14. Vandenbeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6 mediated "acute-phase response" in the brain? Immunol Today 1991;12:217-219
15. 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990; 28:561-567
16. Brugge K, Katzman R, Hill LR, et al. Serological α-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients. Dementia 1995;6:17-20
17. 1 antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients. Dementia 1995;5:17-20
18. Mohs RC, Silverman JM, Breitner JCS, et al. Alzheimer's disease: morbid risk among first degree relatives approximated 50% by age 90. Arch Gen Psychiatry 1987;44:405-408
19. Goldgaber D, Harris H, Hla T, et al. Interleukin-1 regulates synthesis of amyloid beta protein precursor mRNA in human endothelial cell. Proc Natl Acad Sci U S A 1989;86:7606-7610
20. Fagarasan MO, Aisen PS. Il-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in PC12 cells. Brain Res 1996;723:231-234
21. Rogers J, Schultz J, Brachova L, et al. Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res Immunol 1992;143:624-630
22. Rogers J, Cooper NR, Webster S, et al. Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A 1992;89: 10,016-10,020
23. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-232
24. Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16:523-530
25. Aisen PS, Marin D, Altsteil L, et al. A pilot study of prednisone in Alzheimer's disease. Dementia 1996;7:201-206
26. Aisen PS, Altsteil L, Marin D, et al. Treatment of Alzheimer's disease with prednisone: results of pilot studies and design of multicenter trial [abstract]. J Am Geriatr Soc 1995;43:SA27